Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation

about

Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant.

P2860

Q48098399-4E7699F4-3BB4-4872-833B-93A9868C061E

P2860

Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation

Item

http://www.wikidata.org/entity/Q41791124

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Rituximab is highly effective ...... etic stem cell transplantation

@en

type

Item

label

Rituximab is highly effective ...... etic stem cell transplantation

@en

prefLabel

Rituximab is highly effective ...... etic stem cell transplantation

@en

P1476

Rituximab is highly effective ...... etic stem cell transplantation

@en

P2093

Andrzej Frankiewicz

http://www.w3.org/2001/XMLSchema#string

Anna Kopińska

http://www.w3.org/2001/XMLSchema#string

Iwona Grygoruk-Wiśniowska

http://www.w3.org/2001/XMLSchema#string

Sławomira Kyrcz-Krzemień

http://www.w3.org/2001/XMLSchema#string

P2860

Post-transplant lymphoproliferative disorder: a review.

Treatment of Epstein-Barr virus--associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review.

Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.

Rituximab-associated infections.

Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia.

Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation.

After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B.

Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.

Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation.

P304

215-217

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.5114/WO.2012.29287

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Grzegorz Helbig

P577

2012-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

240310203

http://www.w3.org/2001/XMLSchema#string

P698

23788882

http://www.w3.org/2001/XMLSchema#string

P921

Post-transplant lymphoproliferative disorder

P932

3687412

http://www.w3.org/2001/XMLSchema#string

Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation

about

P2860

P2860

Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932